OOIR: Observatory of International Research

Papers

(The TQCC of Biopharmaceutics & Drug disPosition is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit?	19
	17
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats	16
	16
	15
	14
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine	11
Issue Information	11
Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug‐drug interactions with rivaroxaban	10
Comparison of biomarker and chromatographic analytical approaches to pharmacokinetic study of sitagliptin	10
	10
	8
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study	8
Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants	8
Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel	8
Heterogeneous brain distribution of bumetanide following systemic administration in rats	7
Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro	7
Issue Information	7
	6
Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates—The impact of metabolising enzyme ontogeny and reduced cardiac output	6
	6
Changes in uridine 5′‐diphospho‐glucuronosyltransferase 1A6 expression by histone deacetylase inhibitor valproic acid	6
	6
Issue Information	5
	5

Influence of Gegenqinlian decoction on pharmacokinetics and pharmacodynamics of saxagliptin in type 2 diabetes mellitus rats	5
In Vivo Animal Spices and Experimental Technique to Evaluate Sustained Release Granules	5
Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system	5
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery	5
	5
	5
In vitro evaluation of ^99mTc‐sultamicillin for infection imaging	4
Profiling pharmacokinetics of double‐negative T cells and cytokines via a single intravenous administration in NSG mice	4
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs	4
Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial	4
Regional distributions of curcumin and tetrahydrocurcumin in the liver and small intestine of rats when orally co‐administered with quercetin and paeoniflorin	4
Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT₆ receptor occupancy from non‐human primates to humans	4
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐81	4
Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia	3
	3
Linking in vitro–in vivo extrapolations with physiologically based modeling to inform drug and formulation development	3
Absorption, metabolism, and pharmacokinetic profile of xanthohumol in rats as determined via UPLC‐MS/MS	3
	3
	3
Effect of hepar‐protecting Wuzhi capsule on pharmacokinetics and dose‐effect character of tacrolimus in healthy volunteers	3
Issue Information	3
In vitro–in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapo	3
	3
When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations	3
Decreased plasma acetaminophen glucuronide/acetaminophen concentration ratio warns the onset of acetaminophen‐induced liver injury	3
The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study	3